Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OptumRx Inc.
High-Priced Drugs For Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts And ICER
There are as many rare disease patients as there are diabetics, Cigna’s Steve Miller notes, arguing that exorbitant prices for each treatment could drive counterproductive categorical exclusions by payers.
Plus: Korean firms working on repurposed drug which showed far higher efficacy than remdesivir and chloroquine in pre-clinical tests
Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.
Getting doctors to prescribe lower cost biologics has become less of a challenge as additional products reach the market in the US, according to panelists at the World Biosimilar Congress.